KZIA
Kazia Therapeutics Limited
NASDAQ · Healthcare · Biotechnology · AU
$12.31
+1.23%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -9.7%
- EBIT
- +19.4%
- EPS
- +61.7%
- Free cash flow
- +49.7%
- Operating cash flow
- +37.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +61.3%
- EBITDA
- +50.1%
- EBIT
- +50.0%
- Net income
- +22.7%
- EPS
- +65.6%
- Free cash flow
- -38.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025